SMO and medulloblastoma: Mutations within the drug-binding pocket of the Smoothened (SMO) receptor are reported among basal cell carcinoma (BCC) and medulloblastoma patients who become resistant to the SHH/SMO inhibitor, Vismodegib [16, 17] (Figure 2).